ES3024469T3 - Antibodies that bind to sortilin and inhibit the binding of progranulin - Google Patents
Antibodies that bind to sortilin and inhibit the binding of progranulin Download PDFInfo
- Publication number
- ES3024469T3 ES3024469T3 ES16739087T ES16739087T ES3024469T3 ES 3024469 T3 ES3024469 T3 ES 3024469T3 ES 16739087 T ES16739087 T ES 16739087T ES 16739087 T ES16739087 T ES 16739087T ES 3024469 T3 ES3024469 T3 ES 3024469T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- variable domain
- chain variable
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512215.3A GB201512215D0 (en) | 2015-07-13 | 2015-07-13 | Agents,uses and methods |
| PCT/EP2016/066516 WO2017009327A1 (en) | 2015-07-13 | 2016-07-12 | Antibodies that bind to sortilin and inhibit the binding of progranulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3024469T3 true ES3024469T3 (en) | 2025-06-04 |
Family
ID=54013862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16739087T Active ES3024469T3 (en) | 2015-07-13 | 2016-07-12 | Antibodies that bind to sortilin and inhibit the binding of progranulin |
Country Status (35)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10849992B1 (en) | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
| JP6999421B2 (ja) | 2015-04-07 | 2022-02-04 | アレクトル エルエルシー | 抗ソルチリン抗体及びその使用方法 |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10894833B2 (en) * | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| KR102530517B1 (ko) * | 2018-07-13 | 2023-05-09 | 알렉터 엘엘씨 | 항-소틸린 항체 및 이들의 사용 방법 |
| EP3666281A1 (en) * | 2018-12-14 | 2020-06-17 | Insusense ApS | Compositions comprising sortilin-1 |
| JP2023507846A (ja) * | 2019-12-23 | 2023-02-27 | デナリ セラピューティクス インコーポレイテッド | プログラニュリン変異体 |
| IL299329A (en) | 2020-06-24 | 2023-02-01 | Prothena Biosciences Ltd | Antibodies recognizing sortilin |
| CN119403786A (zh) | 2022-06-23 | 2025-02-07 | 德罗普尼尔生物有限公司 | 选择性诱导细胞外靶标在溶酶体中降解的双功能分子 |
| CN118496354A (zh) * | 2023-02-15 | 2024-08-16 | 三优生物医药(上海)有限公司 | 包含共同轻链的抗体库、其制备方法及其用途 |
| WO2025031098A1 (zh) * | 2023-08-09 | 2025-02-13 | 瑞诺元(苏州)生物科技有限公司 | 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用 |
| WO2025132764A1 (en) * | 2023-12-21 | 2025-06-26 | Amylonix Ab | A sortilin-binding polypeptide |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0486622B1 (en) | 1989-08-09 | 1998-11-04 | Rhomed, Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5101990A (en) | 1990-03-23 | 1992-04-07 | Continental Pet Technologies, Inc. | Stretch blow molded oblong or oval container |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| ES2146648T3 (es) | 1993-03-09 | 2000-08-16 | Genzyme Corp | Procedimiento de aislamiento de proteinas de la leche. |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| IL144084A0 (en) | 1999-02-03 | 2002-05-23 | Biosante Pharmaceuticals Inc | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| ES2380055T3 (es) | 2002-12-20 | 2012-05-08 | H. Lundbeck A/S | Modulación de la actividad de neurotrofinas; método de escrutinio |
| EA016609B1 (ru) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Рекомбинантные моновалентные антитела и способы их получения |
| US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
| SI3225251T1 (sl) | 2006-12-21 | 2020-03-31 | H. Lundbeck A/S | Modulacija aktivnosti pronevrotrofinov |
| EP2185692A4 (en) | 2007-08-10 | 2012-05-02 | Medarex Inc | HCO32 AND HCO27 AND RELATED EXAMPLES |
| JP5715045B2 (ja) | 2008-04-27 | 2015-05-07 | ハー・ルンドベック・アクチエゼルスカベット | ソルチリンに対する特異的リガンドの設計 |
| US8420784B2 (en) | 2008-05-27 | 2013-04-16 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor, (IL-10R) antibodies |
| US20120039865A1 (en) | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| EP3165537A1 (en) | 2008-12-19 | 2017-05-10 | H. Lundbeck A/S | Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| RU2536232C2 (ru) * | 2011-07-01 | 2014-12-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера |
| US9822366B2 (en) | 2012-11-02 | 2017-11-21 | The Brigham And Women's Hospital, Inc. | Sortilin 1 is a novel inducer of vascular calcification |
| JP6999421B2 (ja) | 2015-04-07 | 2022-02-04 | アレクトル エルエルシー | 抗ソルチリン抗体及びその使用方法 |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| KR102530517B1 (ko) | 2018-07-13 | 2023-05-09 | 알렉터 엘엘씨 | 항-소틸린 항체 및 이들의 사용 방법 |
-
2015
- 2015-07-13 GB GBGB1512215.3A patent/GB201512215D0/en not_active Ceased
-
2016
- 2016-07-11 JO JOP/2016/0141A patent/JO3710B1/ar active
- 2016-07-12 CA CA2989739A patent/CA2989739A1/en active Pending
- 2016-07-12 MA MA42440A patent/MA42440B1/fr unknown
- 2016-07-12 PE PE2018000064A patent/PE20181014A1/es unknown
- 2016-07-12 WO PCT/EP2016/066516 patent/WO2017009327A1/en not_active Ceased
- 2016-07-12 UA UAA201800574A patent/UA125136C2/uk unknown
- 2016-07-12 KR KR1020187001192A patent/KR102778576B1/ko active Active
- 2016-07-12 US US15/743,549 patent/US10479835B2/en active Active
- 2016-07-12 JP JP2018501182A patent/JP6979397B2/ja active Active
- 2016-07-12 RS RS20250507A patent/RS66856B1/sr unknown
- 2016-07-12 CN CN201680040476.5A patent/CN107849135A/zh active Pending
- 2016-07-12 ES ES16739087T patent/ES3024469T3/es active Active
- 2016-07-12 CN CN202210124752.3A patent/CN114478775A/zh active Pending
- 2016-07-12 CR CR20180002A patent/CR20180002A/es unknown
- 2016-07-12 AR ARP160102109A patent/AR105335A1/es not_active Application Discontinuation
- 2016-07-12 EA EA201890038A patent/EA201890038A1/ru unknown
- 2016-07-12 US US15/207,880 patent/US10428147B2/en active Active
- 2016-07-12 EP EP16739087.1A patent/EP3322726B1/en active Active
- 2016-07-12 AU AU2016292980A patent/AU2016292980B2/en active Active
- 2016-07-12 PL PL16739087.1T patent/PL3322726T3/pl unknown
- 2016-07-12 MX MX2018000506A patent/MX2018000506A/es unknown
- 2016-07-12 HU HUE16739087A patent/HUE071424T2/hu unknown
- 2016-07-12 TN TNP/2017/000534A patent/TN2017000534A1/en unknown
- 2016-07-12 CN CN202210124751.9A patent/CN114478774A/zh active Pending
- 2016-07-12 TW TW105121903A patent/TWI760305B/zh not_active IP Right Cessation
- 2016-07-12 RU RU2018100824A patent/RU2735639C2/ru active
- 2016-07-12 BR BR112018000771-4A patent/BR112018000771A2/pt not_active IP Right Cessation
- 2016-07-12 HR HRP20250602TT patent/HRP20250602T1/hr unknown
-
2017
- 2017-12-18 CO CONC2017/0012988A patent/CO2017012988A2/es unknown
- 2017-12-18 ZA ZA2017/08613A patent/ZA201708613B/en unknown
- 2017-12-22 IL IL256503A patent/IL256503B/en unknown
-
2018
- 2018-01-11 DO DO2018000014A patent/DOP2018000014A/es unknown
- 2018-01-11 PH PH12018500100A patent/PH12018500100A1/en unknown
- 2018-01-11 CL CL2018000092A patent/CL2018000092A1/es unknown
- 2018-01-11 NI NI201800007A patent/NI201800007A/es unknown
- 2018-01-11 SV SV2018005613A patent/SV2018005613A/es unknown
- 2018-01-12 EC ECIEPI20182725A patent/ECSP18002725A/es unknown
-
2019
- 2019-07-24 US US16/521,279 patent/US10889650B2/en active Active
-
2020
- 2020-09-24 CL CL2020002468A patent/CL2020002468A1/es unknown
- 2020-11-13 US US17/097,457 patent/US11548950B2/en active Active
-
2021
- 2021-09-17 JP JP2021151783A patent/JP2022003058A/ja active Pending
-
2022
- 2022-11-18 US US18/057,104 patent/US12331123B2/en active Active
-
2025
- 2025-05-16 US US19/210,142 patent/US20250277040A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3024469T3 (en) | Antibodies that bind to sortilin and inhibit the binding of progranulin | |
| ES3028882T3 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| ES2862427T3 (es) | Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos | |
| KR102800556B1 (ko) | 치료를 위한 제제, 용도 및 방법 | |
| EP4637927A1 (en) | Anti-tgfbeta receptor 1 antibodies and uses thereof | |
| HK1254356B (en) | Antibodies that bind to sortilin and inhibit the binding of progranulin |